Rotavirus

Emerging Infectious Diseases

Volumn 4, Issue 4, 1998, Pages 561-570

  Parashar, Umesh D ^a   Bresee, Joseph S ^a   Gentsch, Jon R ^a   Glass, Roger I ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; DIARRHEA; HUMAN; INFECTION PREVENTION; INFECTION RISK; REVIEW; ROTAVIRUS; TREATMENT OUTCOME;

EID: 0031761674     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0404.980406     Document Type: Review

References (52)

1. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973;1:1281-3.
2. de Zoysa I, Feachem RV. Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunisation. Bull World Health Organ 1985;63:569-83.
3. Kapikian AZ, Chanock RM. Rotaviruses. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Monath TP, Melnick JL, et al., editors. Fields virology, 3rd ed. Vol. 2. New York: Raven Press; 1996: p. 1657-708.
4. Estes MK. Rotaviruses and their replication. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Monath TP, Melnick JL, et al, editors. Fields virology, 3rd ed. Vol. 2. New York: Raven Press; 1996. p. 1625-55.
5. Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus specific diagnostic code. J Infect Dis 1998;177:7-13.
6. Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 1998;279:1371-6.
7. Institute of Medicine. The prospects of immunizing against rotavirus. In: New vaccine development: diseases of importance in developing countries, Vol. 2. Washington: National Academy Press; 1986. p. D-13 to D-13-2.
8. Glass RI, Bresee JS, Parashar UD, Miller MA, Gentsch JR. Rotavirus vaccines at the threshold. Nat Med 1997;3:10-1.
9. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983;309:72-6.
10. Velazquez FR, Matson DO, Calva JJ, Guerrero ML, Morrow AL, Carter-Campbell S, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8.
11. Gentsch JR, Woods PA, Ramachandran M, Das BK, Leite JP, Alfieri A, et al. Review of G and P typing results from a global collection of rotavirus strains: implication for vaccine development. J Infect Dis 1996;174:S30-6.
12. Ramachandran M, Das BK, Vij A, Kumar R, Bhambal SS, Kesari N, et al. Unusual diversity of human rotavirus G and P genotypes in India. J Clin Microbiol 1996;34:436-9.
13. Cicirello HG, Das BK, Gupta A, Bhan MK, Gentsch JR, Kumar R, et al. High prevalence or rotavirus infection among neonates born at hospitals in Delhi, India: predisposition of newborns for infection with unusual rotavirus. Ped Infect Dis J 1994;13:720-4.
14. Cook SM, Glass RI, LeBaron CW, Ho M-S. Global seasonality of rotavirus infections. Bull World Health Organ 1990;68:171-7.
15. Török TJ, Kilgore PE, Clarke MJ, Holman RC, Bresee JS, Glass RI. Visualizing geographic and temporal trends in rotavirus activity in the United States, 1991 to 1996. Pediatr Infect Dis J 1997;16:941-6.
16. Nakagomi O, Nakagomi T. Genetic diversity and similarity among mammalian rotaviruses in relation to interspecies transmission of rotavirus. Arch Virol 1991;120:43-55.
17. Ward R. Mechanisms of protection against rotavirus in humans and mice. J Infect Dis 1996;174:S51-8.
18. Offit PA. Host factors associated with protection against rotavirus disease: the skies are clearing. J Infect Dis 1996;174:859-64.
19. Ebina T, Sato A, Umezu K, Ishida N, Ohyama S, Ohizumi A, et al. Prevention of rotavirus infection with cow colostrum containing antibody against human rotavirus. Lancet 1983;2:1029-30.
20. Hilpert H, Brussow H, Mietens C, Sidoti J, Lerner L, Werchau H. Use of bovine milk concentrate antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis 1987;156:158-66.
21. Kapikian AZ. Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea in infants and young children: an introduction. In: Kapikian AZ, editor. Viral infections of the gastrointestinal tract. Vol 2. New York Marcel Dekker; 1994. p. 409-17.
22. Vesikari T, Isolauri E, d'Hondt E. Protection of infants against rotavirus diarrhea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984;1:977-81.
23. Vesikari T, Isolauri E, Delem A, d'Hondt E, Andre FE, Beards GM, et al. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 1985;107:189-94.
24. Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine (at birth and 7 months of age) for prevention of rotavirus diarrhea. Acta Paediatrica Scandinavica 1991;80:173-80.
25. Ruuska T, Vesikari T, Delem A, Andre FE, Beards GM, Flewett TH. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy and season of birth in relation to rotavirus epidemic period. Scand J Infect Dis 1990;22:269-78.
26. Santosham M, Letson WG, Wolff M, Reid R, Gahagan S, Adams R, et al. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population. J Infect Dis 1991;163:483-7.
27. Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987;1:1342-5.
28. DeMol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986;1:108.
29. Lanata CF, Black RE, del Aguila R, Gil A, Verastegui H, Gerna G, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989;159:452-9.
30. Clark HF, Borian FE, Bell LM, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988;158:570-87.
31. Bernstein DI, Smith VE, Sander DS, Pax KA, Schiff GM, Ward RL. Evaluation of WCS rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 1990;162:1055-62.
32. Georges-Courbot MC, Monges J, Siopathis MR, Roungou JB, Gresenguet G, Bellec L, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991;142:405-11.
33. Rennels MB, Losonsky GA, Levine MM, Kapikian AZ. Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children. Pediatr Infect Dis J 1986;5:587-8.
34. Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian AZ, Glass RI. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J Infect Dis 1989;159:753-7.
35. Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefsky D, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988;7:645-50.
36. Rennels MB, Losonsky GA, Young AE, Shindledecker CL, Kapikian AZ, Levine MM. An efficacy trial of the rhesus rotavirus vaccine in Maryland. The clinical study group. Am J Dis Child 1990;144:601-4.
37. Vesikari T, Rautenen T, Varis T, Beards GM, Kapikian AZ. Rhesus rotavirus candidate vaccine. Am J Dis Child 1990;144:285-9.
38. Madore HP, Christy C, Pichichero M, Long C, Pincus P, Vosefsky D, et al. Field trial of rhesus rotavirus or human-rhesus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. J Infect Dis 1992;166:235-43.
39. Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, et al. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol 1990;30:219-29.
40. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996;174:865-72.
41. Perez-Schael I, Guntinas MJ, Perez M, Pagone V, Rojas AM, Gonzlez R, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997;337:1181-7.
42. Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. A randomized, double-blind placebo controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350:1205-9.
43. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito PT, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the national multicenter trial. Pediatrics 1996;97:7-13.
44. Santosham M, Moulton LH, Reid R, Croll J, Weatherholt R, Ward R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997;131:632-8.
45. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, U.S. Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in U.S. children. JAMA 1995;273:1191-6.
46. Lanata CF, Midthun K, Black RE, Lazo F, Butron B, Linares A, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996;174:268-75.
47. Linhares AC, Gabbay YB, Mascarenhas JDP, deFreitas RB, Oliveira CS, Bellesi N, et al. Immunogenicity, safety, and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 1996;74:491-500.
48. Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996;174:873-80.
49. Vesikari T, Ruuska T, Koivu H, Green KY, Flores J, Kapikian AZ. Evaluation of the M37 human rotavirus vaccine in 2- to 6-month-old infants. Pediatr Infect Dis J 1991;10:912-7.
50. Connor ME, Zarley CD, Hu B, Parsons S, Drabinski D, Greiner S, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis 1996;174:S88-92.
51. Herrmann JE, Chen SC, Fynan EF, Santoro JC, Greenberg HB, Wang S, et al. Protection against rotavirus infections by DNA vaccination. J Infect Dis 1996;174:S93-7.
52. Hausdorff WP. Prospects for the use of new vaccines in developing countries: cost is not the only impediment. Vaccine 1996;14:1179-86.